Grimes & Company Inc. Sells 1,122 Shares of ADMA Biologics Inc (NASDAQ:ADMA)

Grimes & Company Inc. decreased its position in ADMA Biologics Inc (NASDAQ:ADMA) by 4.9% in the 1st quarter, HoldingsChannel.com reports. The fund owned 21,690 shares of the biotechnology company’s stock after selling 1,122 shares during the quarter. Grimes & Company Inc.’s holdings in ADMA Biologics were worth $430,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. B Group Inc. bought a new position in shares of ADMA Biologics during the fourth quarter valued at about $39,231,000. Raymond James Financial Inc. purchased a new stake in ADMA Biologics in the 4th quarter valued at about $19,076,000. Arrowstreet Capital Limited Partnership lifted its position in shares of ADMA Biologics by 57.9% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 2,762,700 shares of the biotechnology company’s stock worth $47,380,000 after buying an additional 1,013,456 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of ADMA Biologics by 16.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 4,668,320 shares of the biotechnology company’s stock worth $80,065,000 after buying an additional 643,661 shares in the last quarter. Finally, Man Group plc boosted its stake in shares of ADMA Biologics by 305.5% in the 4th quarter. Man Group plc now owns 745,300 shares of the biotechnology company’s stock worth $12,782,000 after buying an additional 561,507 shares during the last quarter. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Stock Down 7.4%

ADMA opened at $18.89 on Wednesday. ADMA Biologics Inc has a twelve month low of $10.21 and a twelve month high of $25.67. The company’s 50-day moving average price is $20.98 and its two-hundred day moving average price is $18.83. The stock has a market cap of $4.51 billion, a price-to-earnings ratio of 22.22 and a beta of 0.47. The company has a quick ratio of 3.36, a current ratio of 6.58 and a debt-to-equity ratio of 0.22.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.02). ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. The company had revenue of $114.80 million during the quarter, compared to the consensus estimate of $116.40 million. During the same period last year, the firm posted $0.08 EPS. The company’s revenue for the quarter was up 40.2% compared to the same quarter last year. As a group, equities analysts expect that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

Insider Buying and Selling at ADMA Biologics

In other news, Director Jerrold B. Grossman sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $21.31, for a total value of $213,100.00. Following the sale, the director now owns 478,194 shares of the company’s stock, valued at $10,190,314.14. The trade was a 2.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Lawrence P. Guiheen sold 7,779 shares of the company’s stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $20.32, for a total transaction of $158,069.28. Following the sale, the director now owns 114,830 shares in the company, valued at $2,333,345.60. The trade was a 6.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 464,621 shares of company stock worth $9,644,269 over the last ninety days. 3.70% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Wall Street Zen downgraded ADMA Biologics from a “hold” rating to a “sell” rating in a research report on Friday, May 9th. Raymond James Financial upped their price objective on ADMA Biologics from $25.00 to $32.00 and gave the company a “strong-buy” rating in a research note on Thursday, May 8th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $25.00 target price on shares of ADMA Biologics in a research report on Tuesday, March 4th. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $24.25.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.